Margaux Hall is a partner in the firm’s nationally recognized health care practice, based in Washington, D.C. Margaux is a leading lawyer in drug pricing, market access and value-based arrangements. She brings to clients an understanding of the transformative legal and policy issues and market changes affecting pricing, reimbursement, coverage and access to drugs, vaccines and devices, including in the wake of the COVID-19 pandemic.
Recognized by Chambers and other publications, Margaux provides sophisticated regulatory and strategic business counsel to clients – including pharmaceutical manufacturers, investors, and others – on matters involving coverage and reimbursement under Medicare Advantage-Part D, Medicaid, the Federal Supply Schedule, and other government programs; innovative contracting and payment arrangements under government and commercial contracts; and price reporting obligations under federal and state laws.
Margaux’s deep knowledge of the pharmaceutical supply chain also is invaluable in major life sciences transactions. Investors and others turn to Margaux to assist them in assessing and evaluating their investments in pharmaceutical products, specialty and long-term care pharmacies, pharmacy benefit managers, distributors, group purchasing organizations, and other companies providing services to entities in the supply chain.
Margaux has dedicated her career to understanding health care in the U.S. and worldwide; after graduating from Harvard Law School, she pursued a Fulbright Fellowship to research health care law and health system reform in South Africa and then led similar research programs at the World Bank. Margaux also completed a post-graduate fellowship focusing on health law through Columbia Law School.
Margaux also has developed a robust practice with pro bono clients in the health care arena. As part of this, she has long represented Capital Clubhouse, a nonprofit organization serving people living with mental illness, during its creation of a community health center.